While these previous studies suggested that changes in the serum levels of TRAIL might be related to the development of atherosclerotic disease [5], [6], as we have confirmed in a mouse model of atherosclerosis [21], our present study is the first to provide follow-up analysis of the TRAIL levels at various time points after AMI and to indicate that the decreased serum levels of TRAIL might have a negative prognostic significance in AMI patients. Here, TNFSF10 is linked to atherosclerosis.